Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.
- 1 November 1992
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 86 (5), 1370-1375
- https://doi.org/10.1161/01.cir.86.5.1370
Abstract
BACKGROUND In this study, the anticoagulant response of 12,500 IU heparin s.c. was investigated in patients with myocardial infarction and healthy volunteers to determine variabilities in response and modifying factors. METHODS AND RESULTS On the fourth day after thrombolytic therapy, blood samples were taken before and at frequent intervals until 10 hours after the injection of 12,500 IU heparin s.c. Plasma anti-Xa activity, anti-IIa activity, and the activated partial thromboplastin time (APTT) were measured in addition to body weight and thickness of the abdominal subcutaneous fat layer. Contrary to expectations, the increase of anti-Xa activity, anti-IIa activity, and APTT compared with baseline (predrug) levels was very small, with an average maximal APTT of 42.6 seconds (SD, 12.4 seconds; range, 30.4-70.7 seconds). Subsequently, the influence of the length of the injection needle on the anticoagulant effect of 12,500 IU heparin s.c. was studied in 10 healthy volunteers to find a factor that could be responsible for the poor response in the patients. The length of the injection needle did not influence the anticoagulant effect of heparin. Large interindividual and intraindividual variabilities were seen in the volunteers. The majority of volunteers had minimal prolongation of the APTT, but very strong prolongation was also seen (maximal APTT, 163 seconds). There was no correlation between the abdominal skinfold thickness and anti-Xa activity, anti-IIa activity, or APTT (p > 0.05), but in the patient study, there was a correlation between weight and anti-Xa activity and anti-IIa activity (p < 0.05), and in the volunteer study, there was a correlation between weight and anti-Xa activity and APTT (p < 0.05). CONCLUSIONS Subcutaneous administration of heparin in a fixed dose for prophylactic and therapeutic purposes may be inadequate because of the large interindividual and intraindividual variations in anticoagulant effect.Keywords
This publication has 17 references indexed in Scilit:
- Influence of skinfold thickness on heparin absorptionThe Lancet, 1991
- Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormalityAmerican Heart Journal, 1990
- Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial InfarctionNew England Journal of Medicine, 1989
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous HeparinNew England Journal of Medicine, 1988
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986
- Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarctionJournal of the American College of Cardiology, 1986
- Prophylaxis of Venous ThromboembolismAnnals of Surgery, 1980
- Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238)Thrombosis Research, 1978
- Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin IIIThrombosis Research, 1977